AQS — Aequus Pharmaceuticals Share Price
Last Trade - 00:00- CA$17.24m
- CA$15.99m
- CA$2.50m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.7 | 1.14 | 1.41 | 1.63 | 2.59 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products. The Company operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. Its products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release (XR), which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product. Its development-stage pipeline includes various products in neurology and psychiatry. Its lead development-stage product candidate is AQS-1301. In addition, the Company is developing a pipeline of other central nervous system product candidates. It has over two preclinical-stage programs and a clinical-stage program in development.
Directors
- Douglas Janzen
- Ann Fehr CFO (50)
- Anne Stevens COO
- Don McAfee
- Christopher Clark
- Marc Lustig
- Jason Flowerday
- Stuart Fowler
- Rodoula Plakogiannis IND
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- January 3rd, 2013
- Public Since
- March 17th, 2015
- No. of Employees
- 13
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 132,634,431
- Address
- 2820-200 GRANVILLE STREET, VANCOUVER, BC V6C 1S4
- Web
- http://www.aequuspharma.ca/
- Phone
- +1 6043367906
- Auditors
- Dale Matheson Carr-Hilton LaBonte LLP
Latest News for AQS
Upcoming events for AQS
Similar to AQS
BIOSYENT ORD
TSX Venture Exchange
DEVONIAN HEALTH GROU ORD
TSX Venture Exchange
ELIXXER ORD
TSX Venture Exchange
ENTOURAGE HEALTH ORD
TSX Venture Exchange
HARVEST ONE CANNABIS ORD
TSX Venture Exchange
FAQ
As of Today at 19:56 UTC, shares in Aequus Pharmaceuticals are trading at CA$0.13. This share price information is delayed by 15 minutes.
Shares in Aequus Pharmaceuticals last closed at CA$0.13 and the price had moved by +13.64% over the past 365 days. In terms of relative price strength the Aequus Pharmaceuticals share price has underperformed the Toronto Stock Exchange 300 Composite Index by -7.92% over the past year.
There is no consensus recommendation for this security.
Aequus Pharmaceuticals does not currently pay a dividend.
Aequus Pharmaceuticals does not currently pay a dividend.
Aequus Pharmaceuticals does not currently pay a dividend.
To buy shares in Aequus Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.13, shares in Aequus Pharmaceuticals had a market capitalisation of CA$17.24m.
Here are the trading details for Aequus Pharmaceuticals:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: AQS
Based on an overall assessment of its quality, value and momentum Aequus Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aequus Pharmaceuticals. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -51.3%.
As of the last closing price of CA$0.13, shares in Aequus Pharmaceuticals were trading -13.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Aequus Pharmaceuticals.
Aequus Pharmaceuticals' management team is headed by:
- Douglas Janzen -
- Ann Fehr - CFO
- Anne Stevens - COO
- Don McAfee -
- Christopher Clark -
- Marc Lustig -
- Jason Flowerday -
- Stuart Fowler -
- Rodoula Plakogiannis - IND
We do not have data on Aequus Pharmaceuticals' shareholders